In patients receiving EPC stent, microvascular dysfunction was reduced compared with patients receiving 2nd generation drug eluting stent. Rapid endothelialization by EPC stent may be desired in some patients predicting microvascular dysfunction in DES era.
Conclusion:
In patients with no-reflow, oxidants are increased, while serum paraoxonase-1 activity and antioxidants are decreased. This result shows that increased oxidative stress may have role in the pathogenesis of no-reflow.
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Influence of endothelial progenitor cell captureing stent on coronary microvascular function in drug eluting stent era 
Conclusion:
In patients receiving EPC stent, microvascular dysfunction was reduced compared with patients receiving 2nd generation drug eluting stent. Rapid endothelialization by EPC stent may be desired in some patients predicting microvascular dysfunction in DES era.
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Lipoprotein-phospholipase A2 is associated with increased arterial stiffness and abnormal wave reflections linked with impaired coronary flow in patients with CAD Lipoprotein phospholipase A2 (Lp-PLA2) is an emerging inflammatory marker with prognostic value. Aortic wall properties and wave reflections determine coronary perfusion, LV function and have an independent prognostic value. We investigated the association of Lp-PLA2 with arterial stiffness and abnormal wave reflections in CAD patients. Methods: We assessed in 70 patients with angiographically documented CAD. We measured pulse wave velocity using both the Complior (carotid to femoralPWVc) and Arteriograph apparatus (PWVa-oscillometric method). By means of pulse wave analysis (Arteriograph apparatus) we calculated the augmentation index (AI) of the arterial wave reflection, the diastolic area (DAI%) of the aortic pulse wave and diastolic reflection area (DRA), an index of diastolic filling of coronary arteries derived by duration of diastole and area between the expected area of the diastolic pressure curve without wave reflection and the true area with wave reflection. Patients were also categorised into 2 subgroups according to the median values of the pulse wave analysis indices. The velocity time integral of the diastolic component of coronary flow of the LAD was assessed using Doppler echocardiography Results: Increasing levels of Lp-PLA2 were related with smoking, increasing PWVc, PWVa, AI and decreasing DAI% and DRA (r=0.41, r=-0.31, r=-0.45 and r=0.38 r=0.47, respectively, p<0.05). Lp-PLA2 was higher in patients with PWVa >10 m/sec than in those with PWVa <10 m/sec (169±48 vs. 117±24 pg/ml, p=0.003), in patients with AI>34% than in those with AI <34% (144±40 vs. 115±29 pg/ml, p=0.02) in patients with DAI <45% than in those with DAI>45% (138±36 vs. 97±40 pg/ml, p=0.015) and in patients with DRA<43 than in those with DRA>43 (141±36 vs. 99±40 pg/ml, p=0.01). Patients with PWVc>11 m/sec had also higher Lp-PLA2 those with PWVc <11 m/sec (171±49 vs. 119±26 pg/ml, p=0.003).A reduced resting coronary flow velocity time integral was related with reduced DAI% and DRA (r=0.36, r=0.40, p<0.05). Conclusions: Increasing levels of Lp-PLA2 are related to impaired aortic wall properties and abnormal wave reflections associated with impaired coronary diastolic filling. This finding suggests a potential role for Lp-PLA2 to identify CAD patients with adverse prognosis. Background: There are limited number of studies about relationship of serum vitamin D level with presence and severity of coronary artery disease. We assessed the relationship between the extent and complexity of coronary artery disease (CAD) assessed by SYNTAX score and 25-hydroxyvitamin D level in patients with stable CAD. Methods: 209 patients with stable CAD (age: 63,1±10,0 years) and 102 control subjects (age 61,3±13,7 years) were included in the study. Serum 25-hydroxyvitamin D was measured using a direct competitive chemiluminescent immunoassay and other biochemical markers were measured in all subjects. Coronary angiography was performed and SS were determined in all patients. Results: Serum 25-hydroxyvitamin D levels of CAD group were lower compared with the control group (p<0,001). Serum 25-hydroxyvitamin D level was independently associated with SYNTAX score (β= -0,396, p<0,001), hypertension (β= -0,183, p=0,003), high sensitive C-reactive protein (β= -0,141, p=0,014) and body mass index (β= -0,135, p=0,023) in patient group (Table 1) . 
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Obstructive sleep apnea is associated with increased inflammatory activity in non-obese patients with coronary artery disease; a cross sectional study Background: Inflammation has a crucial role in the development of coronary artery disease (CAD). Obstructive sleep apnea (OSA) is a common condition in CAD patients and associated with increased inflammation. The impact of OSA on inflammatory activity in CAD is unknown. Methods and results: Inflammatory markers, High-sensitive (Hs)-CRP, Interleukin (IL)-6, IL-8 and Tumor Necrosis Factor (TNF)-α, were studied in a nonobese cohort of revascularized CAD patients with OSA (Apnea Hypopnea-Index [AHI] ≥15 events/h; n=267) and non-OSA (AHI<5 events/h; n=104), respectively. CAD patients with OSA had higher levels of Hs-CRP (3.52 vs 2.41 mg/ml; p=0.011), IL-6 (11.66 vs 6.27 pg/ml; p<0.001), IL-8 (1.81 vs 1.52 pg/ml; p=0.075) and TNFα (6.06 vs 5.41 pg/mL; p=0.019) compared to the levels seen in non-OSA. In a univariate regression analysis, OSA, based on AHI≥15 events/h was significantly correlated with all four biomarkers but only with IL-6 in the multivariate model (Odds Ratio [OR] 1.33, 95% Confidence Interval [CI] 1.08; 1.65). Applying Oxygen Desaturation Index (ODI) ≥5 events/h as a marker of the severity of intermittent hypoxemia in OSA, we found a significant relationship between ODI≥5 events/h and Hs-CRP (OR 1.28; 95% CI 1.02; 1.62) as well as between ODI≥5 and IL-6 (OR 1.35; 95% CI 1.11; 1.64). Conclusion: OSA is independently related with increased inflammatory activity in this non-obese CAD cohort. The inflammatory activity seems to be triggered by intermittent hypoxemia more than the degree of the apneic events per se in OSA. ClinicaTrials.gov; NCT 00519597.
